PATHOME-Drug: a subpathway-based polypharmacology drug-repositioning method

MOTIVATION Drug repositioning reveals novel indications for existing drugs and in particular, diseases with no available drugs. Diverse computational drug repositioning methods have been proposed by measuring either drug-treated gene expression signatures or the proximity of drug targets and disease proteins found in prior networks. However, these methods do not explain which signaling subparts allow potential drugs to be selected, and do not consider polypharmacology, i.e., multiple targets of a known drug, in specific subparts. RESULTS Here, to address the limitations, we developed a subpathway-based polypharmacology drug repositioning method, PATHOME-Drug, based on drug-associated transcriptomes. Specifically, this tool locates subparts of signaling cascading related to phenotype changes (e.g., disease status changes), and identifies existing approved drugs such that their multiple targets are enriched in the subparts. We show that our method demonstrated better performance for detecting signaling context and specific drugs/compounds, compared to WebGestalt and clusterProfiler, for both real biological and simulated datasets. We believe that our tool can successfully address the current shortage of targeted therapy agents. AVAILABILITY The web-service is available at http://statgen.snu.ac.kr/software/pathome. The source codes and data are available at https://github.com/labnams/pathome-drug. SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  Matthew D Segall,et al.  Multi-parameter optimization: identifying high quality compounds with a balance of properties. , 2012, Current pharmaceutical design.

[2]  Diego di Bernardo,et al.  Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis , 2014, Bioinform..

[3]  T. Gilliam,et al.  Molecular triangulation: bridging linkage and molecular-network information for identifying candidate genes in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[5]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[6]  T. Heskes,et al.  The statistical properties of gene-set analysis , 2016, Nature Reviews Genetics.

[7]  Yen‐Hua Huang,et al.  Prioritizing disease candidate genes by a gene interconnectedness-based approach , 2011, BMC Genomics.

[8]  Prashanth Athri,et al.  Web-based drug repurposing tools: a survey , 2019, Briefings Bioinform..

[9]  K. Kojima,et al.  High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival , 2017, BMC Clinical Pathology.

[10]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[11]  Carl Kingsford,et al.  The power of protein interaction networks for associating genes with diseases , 2010, Bioinform..

[12]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[13]  Riccardo Bellazzi,et al.  Network-based target ranking for polypharmacological therapies , 2013, J. Biomed. Informatics.

[14]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[15]  Silvio Bicciato,et al.  GDA, a web-based tool for Genomics and Drugs integrated analysis , 2018, Nucleic Acids Res..

[16]  Martin Lackmann,et al.  Therapeutic targeting of EPH receptors and their ligands , 2013, Nature Reviews Drug Discovery.

[17]  Jihye Kim,et al.  DSigDB: drug signatures database for gene set analysis , 2015, Bioinform..

[18]  Manolis Tsiknakis,et al.  MinePath: Mining for Phenotype Differential Sub-paths in Molecular Pathways , 2016, PLoS Comput. Biol..

[19]  S. Mori,et al.  Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer , 2015, Molecular oncology.

[20]  Q. Xue,et al.  Dasatinib promotes TRAIL‐mediated apoptosis by upregulating CHOP‐dependent death receptor 5 in gastric cancer , 2018, FEBS open bio.

[21]  Bing Zhang,et al.  GLAD4U: deriving and prioritizing gene lists from PubMed literature , 2012, BMC Genomics.

[22]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[23]  Maria Laura Bolognesi,et al.  Harnessing Polypharmacology with Medicinal Chemistry. , 2019, ACS medicinal chemistry letters.

[24]  Jae Yong Cho,et al.  AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. , 2012, Cancer research.

[25]  J. Werner,et al.  A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  D. Richardson,et al.  The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones. , 2015, Pharmacological research.

[27]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[28]  Roded Sharan,et al.  Associating Genes and Protein Complexes with Disease via Network Propagation , 2010, PLoS Comput. Biol..

[29]  C. Lipinski Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[30]  Marc Hafner,et al.  L1000CDS2: LINCS L1000 characteristic direction signatures search engine , 2016, npj Systems Biology and Applications.

[31]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[32]  Chao Wu,et al.  Computational drug repositioning through heterogeneous network clustering , 2013, BMC Systems Biology.

[33]  M. Vidal,et al.  A genome-wide positioning systems network algorithm for in silico drug repurposing , 2019, Nature Communications.

[34]  T Park,et al.  PATHOME: an algorithm for accurately detecting differentially expressed subpathways , 2014, Oncogene.

[35]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[36]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[37]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[38]  Y. Li,et al.  MicroRNA and signaling pathways in gastric cancer , 2014, Cancer Gene Therapy.

[39]  David Botstein,et al.  GO: : TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes , 2004, Bioinform..

[40]  Marco Scutari,et al.  Learning Bayesian Networks with the bnlearn R Package , 2009, 0908.3817.

[41]  Taesung Park,et al.  HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer , 2014, Gut.

[42]  Jing Wang,et al.  WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit , 2017, Nucleic Acids Res..

[43]  Xiang Zhang,et al.  Drug repositioning by integrating target information through a heterogeneous network model , 2014, Bioinform..

[44]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[45]  Armando Blanco,et al.  DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data , 2015, Artif. Intell. Medicine.

[46]  E. Gallo,et al.  Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics , 2020, Molecular Biology Reports.